NTRK1 and pancreatic adenocarcinoma: In a case of pancreatic adenocarcinoma with CTRC-NTRK1 gene fusion, BRAF-V600E mutation emerged when disease progressed with larotrectinib, which previously achieved a PR at its best, then the tumor continued to progress for 2 months even though the treatment was switched to selitrectinib, a next-generation TRK inhibitor (86).